权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MicroRNA profiling in patients with coronary artery disease.

冠状动脉疾病患者的 MicroRNA 分析。

基本信息

批准号：
20590886
负责人：
SATOH Mamoru
金额：
$ 3万
依托单位：
Iwate Medical University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2008
资助国家：
日本
起止时间：
2008 至 2010
项目状态：
已结题

项目摘要

The present study has investigated microRNA biology concerning endothelial cellular injury and vascular inflammation, such as Toll-like receptor 4 (TLR4). Endothelial progenitor cells (EPCs) play an important role in the maintenance of vascular integrity. The physiological role of miR-221/222, a newly discovered class of small RNA, is closely linked to the proliferation of EPCs. In addition,this study demonstrates that lipid lowering therapy (LLT) with atorvastatin increases EPC numbers and decreases miR-221/222 levels in patients with CAD, possibly contributing to the beneficial effects of LLT with atorvastatin in this disorder.TLR4 signal plays an important role in immunity in CAD. One of the let-7 family microRNAs, let-7i, directly regulates Toll-like receptor 4 (TLR4) expression and contributes to immune response. The miR-146a / b regulates TLR4 downstream molecules (IRAK1 and TRAF6). The present study has shown that miR-146a / b were expressed with TLR4 signal in CAD patients, and combined treatment with a statin and RAS blockade might affect these levels. In addition, let-7i played a negative regulator of TLR4 in patients with CAD, and atorvastatin affected TLR4 levels via let-7i.This study demonstrates that treatment with ARB and atrovastatin decreases miR-146a / b and TLR4 signal in patients with CAD, possibly contributing to the anti-atherogenic effects of ARB and statins in this disorder.

本研究探讨了与内皮细胞损伤和血管炎症有关的microRNA生物学，如Toll样受体4（TLR 4）。内皮祖细胞（Endothelial progenitor cells，EPCs）在维持血管完整性中起重要作用。miR-221/222是一类新发现的小RNA，其生理作用与EPCs的增殖密切相关。此外，阿托伐他汀调脂治疗（LLT）可增加冠心病患者EPC数量，降低miR-221/222水平，这可能有助于阿托伐他汀调脂治疗的有益作用。TLR 4信号在冠心病患者的免疫中起重要作用。let-7家族microRNA之一let-7i直接调节Toll样受体4（TLR 4）的表达，并有助于免疫应答。miR-146 a/ B调节TLR 4下游分子（IRAK 1和TRAF 6）。目前的研究表明，miR-146 a/ B在CAD患者中与TLR 4信号一起表达，并且他汀类药物和RAS阻断剂的联合治疗可能会影响这些水平。此外，let-7 i在冠心病患者中起负性调节作用，阿托伐他汀通过let-7 i影响冠心病患者的TLR 4水平。本研究表明，AR B和阿托伐他汀治疗降低了冠心病患者的miR-146 a/ B和TLR 4信号，这可能有助于AR B和他汀类药物在这种疾病中的抗动脉粥样硬化作用。